The p53 tumor suppressor is the most commonly mutated gene in human cancers (Levine, 1997; Ryan et al., 2001) . It is stabilized in response to a variety of stresses, including DNA damage, replication blockade, hypoxia or aberrantly activated cellular or viral oncogenes (Giaccia and Kastan, 1998; Oren, 1999) . The downstream events that follow from p53 stabilization provide a complex network of signals ultimately leading to cell cycle arrest or apoptosis (Ko and Prives, 1996; Vogelstein et al., 2000) . The role of p53 in G1 and G2 checkpoints in response to genotoxic stress has been well documented (Brugarolas et al., 1995; Bunz et al., 1998; Chan et al., 2000; Hermeking et al., 1997; Wang et al., 1999) . However, the contribution of p53 for an S phase checkpoint is less well understood (Zhou and Elledge, 2000) . A recent report by Gottifredi et al. (2001) has demonstrated that p53 accumulates but is functionally impaired when DNA synthesis is blocked. The finding that DNA replication blockade results in stabilization of a transactivationimpaired p53 protein adds complexity to our understanding of the p53 response. Moreover, it then becomes important to understand how and why p53 is stabilized but is transcriptionally impaired and whether this response to replication blockade is a general phenomenon or is cell-type-specific. To address this issue, the present study has been focused to analyse transcription of p53 target genes in normal and cancer cells. Our results demonstrate that p53 accumulates and transactivates its target genes when DNA synthesis is inhibited in normal and cancer cells.
It has been shown that compounds such as hydroxyurea (HU), which inhibits the activity of ribonucleotide reductase and aphidicolin (APH), which blocks DNA polymerase a can cause a reversible G1/S arrest independent of p53 (Linke et al., 1996) . p53 levels do increase in response to DNA blockade by HU and APH and it has been suggested that p53 inhibits entry into mitosis when DNA synthesis is blocked (Taylor et al., 1999) . Recently, Gottifredi et al. (2001) demonstrated that when colorectal cancer cells (HCT116 and RKO) were treated with HU and APH, the transactivation of p53 target genes were impaired even though nuclear localization, phosphorylation, acetylation and stabilization of p53 were observed. Furthermore, this transcriptionally attenuated p53 was incapable of being reactivated by g ionizing radiation (gIR), which is known to be a potent inducer of p53 (Gottifredi et al., 2001) . However, the exact mechanism(s) leading to impairment of p53 function is currently unknown; though several possibilities from involvement of kinases and coactivators to corepressors have been proposed (Gottifredi et al., 2001; Prives and Manley, 2001; Takimoto and ElDeiry, 2001 ). Interesting questions arise regarding how and why cells stabilize and inhibit p53 during S phase blockade and parallels have been drawn to the transforming adenovirus E1A and E1B, which also stabilize and inactivate p53. It is generally assumed that such viruses need to disable the p53 apoptotic pathway for efficient infection to proceed (Debbas and White, 1993 ). An analogous situation has also been proposed in which during the normal course of S phase there are likely to be strand breaks or stalled forks that can initiate signaling events that stabilize p53. However, in S phase the E2F-1 protein is active and when combined with a fully functional p53, is likely to induce cell death (Wu and Levine, 1994) . It has been hypothesized that to avoid such drastic response, the cell must disable or inactivate p53 (Gottifredi et al., 2001) .
We have analysed the transcription of p53 target genes in response to replication inhibitors in normal human mammary epithelial cells (HMEC p53 +/+ and HMEC p53 7/7 ) and normal human osteoblasts (NHOST), in human breast cancer cells (MCF7), and human colorectal cancer cells (RKO, and HCT116). Consistent with earlier observations in RKO cells (Gottifredi et al., 2001; Ji et al., 1997) , our results have also shown that cells arrest in G1 and S phase in response to HU (Figure 1 ). It was reported that cells reenter the cell cycle after release from a DNA replication block in a p53-independent manner (Gottifredi et al., 2001; Ji et al., 1997) . Unlike Gottifredi et al. (2001) , we showed here that p53 not only accumulated but also transactivated its target genes like p21, gadd45, and bax in normal and cancer cells (Figure 2a,b, Figure 4) . Further, it has been demonstrated that transactivation in response to g IR was almost comparable to that occurring in presence of HU and APH both in NHOST and MCF7 cells (Figure 3) . However, as shown in Figure 3 , the induction of p53 target genes like p21 was earlier (at 4 h) in response to DNA damage by g IR as compared to activation at 6 -48 h when treated with replication inhibitors HU and APH (Figures 3 and 4) . To investigate the formal possibility that activation of certain p53-target genes during DNA replication blockade could be a p53-independent phenomenon, we compared the transcriptional response under the same conditions in two different (p53 +/+ and p53 7/7 ) types of human mammary epithelial cells (HMEC). While there was good induction of p53-target genes such as p21, gadd45, and Bax in the p53 +/+ cells in Figure 1 Cell Cycle profile in response to replication blockade by hydroxyurea (HU) exhibiting a G1/S block in MCF7 cells. Exponentially growing cells (40 -60% confluent) were treated with 1.5 mM hydroxyurea. Flow cytometric determination of cell cycle was performed at different time intervals as indicated. NT -Not treated. Briefly, cells were trypsinized, washed with PBS and fixed in 70% ethanol. Fixed cells were suspended in PBS containing propidium iodide (50 mg/ml), RNase A (500 mg/ml) and Triton X (0.5%). Cell cycle analysis was performed using Becton-Dickinson fluorescence activated cell sorting (FACScan) flow cytometer Figure 2 Expression of p53 target genes in response to replication blockade by hydroxyurea and aphidicolin in MCF7 cells. Exponentially growing cells were treated with hydroxyurea (1.5 mM) and aphidicolin (5 mg/ml). RNA and Protein preparations were done at indicated time intervals. NT -Not treated. (a) Transcriptional analysis of p53 target genes by RNase Protection Assay (RPA). RNA isolation and RPA were essentially as described earlier (Das et al., 1995) . Custom human multiprobe template set containing Bcl-x L , p53, gadd45, c-fos, p21, bax, PCNA, L32 and GAPDH was from BDPharmingen (CA, USA). L32 and GAPDH were controls. Multi-probe set was labeled with T7 RNA polymerase in presence of [a-32 P] UTP and was used for RPA as per Pharmingen's protocol. (b) Analysis of p53 accumulation and p21 induction by Western blot analysis. Cell pellet was directly dissolved in 26 sample buffer (0.125 M Tris-Cl, pH 6.8; 4% SDS; 0.2 M DTT and 0.02% bromophenol blue), heated at 958C for 10 min and spun for 5 min to pellet the chromatin. The supernatant (cell lysate) was estimated by Non-Interfering Protein Assay Kit (Geno Technology, Inc., St. Louis, MO, USA). 60 mg of the lysate was electrophoresed and subjected to Western blot analysis using p53 (DO1, Santa Cruz Biotechnology, CA, USA), p21 (C-19, Santa Cruz Biotechnology) and b Actin (Clone AC15, Sigma, St. Louis, MO, USA) antibodies response to HU, those genes were not transactivated in the p53 7/7 cells (Figure 4 , compare a and d) showing that transactivation of p53-target genes in response to replication blockade is indeed a p53-dependent phenomenon. A recent Gene Microarray analysis of the profile of genes activated in HeLa cells during G1/S block by thymidine/aphidicolin had shown that there was no induction of p53 target genes like p21 or gadd45 (Chaudhry et al., 2002) . This could be explained by the fact that HeLa cells are considered functionally null for p53 due to HPV-16 (Wazer et al., 1995) . Gottifredi et al. (2001) had also reported no transactivation of p21, gadd45 and hdm2 in response to replication blockade. Moreover, the attenuated p53 during replication block was not rescued by g-radiation and the authors provide cautionary implications for cancer treatment in that some combination therapies may not always synergize and in some cases could result in noncooperative or even counteracting outcomes. However, our studies in RKO and HCT116 cells have shown transactivation of p53-target genes in response to HU (Figure 4b,c) .
It is well known that certain viral proteins like E1A, E1B (Debbas and White, 1993) and HPV-16 (Wazer et al., 1995) can inactivate p53. It has been reported from our laboratory and by others that E1A is capable of repressing p53-mediated transcriptional activation (Avantaggiati et al., 1997; Gu et al., 1997; Karuppayil et al., 1998; Lill et al., 1997; Scolnick et al., 1997) . It might be possible that certain cellular counterparts of these viral proteins or certain corepressors keep p53 in a state of partial repression during replication blockade in some cell types. For example, HeLa cells usually express human papilloma viral protein E6, which is known to inactivate p53 (Tommasino and Crawford, 1995) . However, our results from experiments in five different cell types clearly demonstrate that p53 is stabilized and was functionally active during replication blockade in different normal and cancer cells, indicating that transcriptionally defective p53 during DNA replication blockade is not a general phenomenon. Moreover, our data clearly showed that transcriptional activation during replication blockade was p53-dependent as p53-target genes were not 7/7 (184AA3). Exponentially growing cells were treated with hydroxyurea (1.5 mM) and RNA was isolated at indicated time intervals. NT -Not treated. Human mammary epithelial cells (HMEC) and HMECp53 7/7 cells were cultured in serum-free mammary epithelial basal medium (obtained from Clonetics) supplemented with bovine pituitary extract (52 mg/ml), human EGF (10 ng/ml), insulin (5 mg/ml), hydrocortisone (0.5 mg/ml). RKO cells were maintained in DMEM supplemented with 10% FBS and HCT116 cells were maintained in McCoy medium supplemented with 10% FBS. Transcription of p53 gene as well as p53 target genes was analysed by RPA. RPA was performed as described for Figure 2 p53 transactivation during replication blockade BK Nayak and GM Das activated under similar conditions in HMEC cells devoid of p53 (HMEC p53 7/7 , Figure 4d ). However, our results do not rule out the possibility that in certain cells under certain conditions p53 may become functionally defective in response to DNA replication blockade. It is possible that different cells have different constellation of signaling pathways activated under different circumstances which determine whether p53 is transcriptionally active or not in response to replication blockade during S phase. Future studies would reveal the mechanisms involved in p53 transactivation during S phase in response to replication blockade in different cells and could have implications in the design of certain combination therapy for cancer treatment.
